Armored human CAR Treg cells with PD1 promoter-driven IL-10 have enhanced suppressive function., PMID:40512855
Arsenic Trioxide Enhances the Efficacy of PD-1 Inhibitors in Hepatocellular Carcinoma by Inducing Immunogenic Cell Death via the ROS/ERS Pathway., PMID:40504080
Stabilized iRGD modification enhances NY-ESO-1 TCR-T infiltration in solid tumors and synergizes with PD-1 blockade., PMID:40445421
NECTIN4 regulates the cell surface expression of CD155 in non-small cell lung cancer cells and induces tumor resistance to PD-1 inhibitors., PMID:40392373
Dual cytokine-engineered macrophages rejuvenate the tumor microenvironment and enhance anti-PD-1 therapy in renal cell carcinoma., PMID:40294469
The Exploration of Indole-Based LSD1-Targeted Inhibitors for Enhanced Immune Response in Gastric Cancer via the PD-L1/PD-1 Axis., PMID:40257403
Novel PD-1-targeted, activity-optimized IL-15 mutein SOT201 acting in cis provides antitumor activity superior to PD1-IL2v., PMID:40250867
Enhancing curcumol delivery through PD-1 targeted nanocarriers: A novel therapeutic approach for prostate cancer., PMID:40220412
Sodium butyrate increases USP5-mediated ubiquitination degradation of GPX4 and enhances anti-cancer efficacy of anti-PD-1 antibody., PMID:40216263
Engineered PD-L1 co-expression in PD-1 knockout and MAGE-C2-targeting TCR-T cells augments the cytotoxic efficacy toward target cancer cells., PMID:40195438
The inhibition of endothelial DLL4-NOTCH1 signaling by 2'-hydroxyflavanone enhances anti-PD-1 therapy in melanoma., PMID:40172769
Soluble CD27 differentially predicts resistance to anti-PD1 alone but not with anti-CTLA-4 in melanoma., PMID:40148586
Dynamic Change of PD-L2 on Circulating Plasma Extracellular Vesicles as a Predictor of Treatment Response in Melanoma Patients Receiving Anti-PD-1 Therapy., PMID:40135876
Upregulation of RIG-I is Critical for Responsiveness to IFN-α Plus Anti-PD-1 in Colorectal Cancer., PMID:40116486
Therapeutic potential of isochlorogenic acid A from Taraxacum officinale in improving immune response and enhancing the efficacy of PD-1/PD-L1 blockade in triple-negative breast cancer., PMID:40109332
Enhanced therapeutic efficacy of anti-PD-1 blockade by targeting LAMP2A inhibits lysosomal degradation of STING and TBK1., PMID:40083918
Early expansion of TIGIT+PD1+ effector memory CD4 T cells via agonistic effect of alefacept in new-onset type 1 diabetes., PMID:40073269
Alterations in PD-L1 succinylation shape anti-tumor immune responses in melanoma., PMID:40069506
Clofazimine enhances anti-PD-1 immunotherapy in glioblastoma by inhibiting Wnt6 signaling and modulating the tumor immune microenvironment., PMID:40053076
PD-1IR2 promotes tumor evasion via deregulating CD8+ T cell function., PMID:40050045
The combination of flaxseed lignans and PD-1/ PD-L1 inhibitor inhibits breast cancer growth via modulating gut microbiome and host immunity., PMID:40048957
High Antigenicity for Treg Cells Confers Resistance to PD-1 Blockade Therapy via High PD-1 Expression in Treg Cells., PMID:40017103
Correlation of HLA-A and HLA-B/C Expression With PD-1 and PD-L1 Expression in Patients With Metastatic Breast Cancer as a Potential Prognosticator of Favorable Survival., PMID:40010968
Preclinical models of immune checkpoint inhibitors-related interstitial pneumonia for anti-PD1 tumor immunotherapy., PMID:39985972
Bispecific antibody simultaneously targeting AGR2 and PD1 mediates cytotoxic T-cell-induced antitumor response in AGR2-dependent manner and inhibits AGR2-induced PDL1 upregulation., PMID:39971962
A combination of PD-1 and TIGIT immune checkpoint inhibitors elicits a strong anti-tumour response in mesothelioma., PMID:39939955
Actinidia eriantha polysaccharide prevents gastric cancer invasion and metastasis via inhibition of PD-1/PD-L1 regulation of macrophage polarization., PMID:39922338
Revisiting of Cancer Immunotherapy: Insight from the Dialogue between Glycolysis and PD-1/PD-L1 Axis in the Tumor Microenvironment., PMID:39897050
High-dose ascorbic acid synergizes with anti-PD1 therapy in non-small cell lung cancer in vitro and in vivo models., PMID:39896806
Tumor-derived extracellular vesicle PD-1 promotes tumor immune evasion via disruption of peripheral T cell homeostasis., PMID:39864541
Anti-correlation of KLRG1 and PD-1 expression in human tumor CD8 T cells., PMID:39832302
PD1-TLR10 fusion protein enhances the antitumor efficacy of CAR-T cells in colon cancer., PMID:39818091
Chimeric antigen receptor macrophages (CAR-M) sensitize HER2+ solid tumors to PD1 blockade in pre-clinical models., PMID:39814734
HDAC and MEK inhibition synergistically suppresses HOXC6 and enhances PD-1 blockade efficacy in BRAFV600E-mutant microsatellite stable colorectal cancer., PMID:39800382
IDO1 inhibitor enhances the effectiveness of PD-1 blockade in microsatellite stable colorectal cancer by promoting macrophage pro-inflammatory phenotype polarization., PMID:39751692
Spatial proteomics reveals sirtuin 1 to be a determinant of T-cell infiltration in human melanoma., PMID:39739311
Circular RNA circPHLPP2 promotes tumor growth and anti-PD-1 resistance through binding ILF3 to regulate IL36γ transcription in colorectal cancer., PMID:39695693
HMGB3 Contributes to Anti-PD-1 Resistance by Inhibiting IFN-γ-Driven Ferroptosis in TNBC., PMID:39660968
Impaired development of memory B cells and antibody responses in humans and mice deficient in PD-1 signaling., PMID:39603236
Development of selective ssDNA micro-probe for PD1 detection as a novel strategy for cancer imaging., PMID:39562585
Insights into the mechanisms of serplulimab: a distinctive anti-PD-1 monoclonal antibody, in combination with a TIGIT or LAG3 inhibitor in preclinical tumor immunotherapy studies., PMID:39497266
Association Between Multisystem Immune-related Adverse Events and Progression-free Survivals in PD-1/PD-L1 Inhibitor Monotherapy., PMID:39477436
CCL2 blockade combined with PD-1/P-selectin immunomodulators impedes breast cancer brain metastasis., PMID:39450648
A splicing isoform of PD-1 promotes tumor progression as a potential immune checkpoint., PMID:39438489
Monoclonal antibody targeting CEACAM1 enhanced the response to anti-PD1 immunotherapy in non-small cell lung cancer., PMID:39426236
Physiologically Achievable Concentration of 2-Deoxy-D-Glucose Stimulates IFN-γ Secretion in Activated T Cells In Vitro., PMID:39408714
Discovery of Benzo[d]oxazoles as Novel Dual Small-Molecule Inhibitors Targeting PD-1/PD-L1 and VISTA Pathway., PMID:39389791
Anti-HER2 biparatopic antibody KJ015 has near-native structure, functional balanced high affinity, and synergistic efficacy with anti-PD-1 treatment in vivo., PMID:39381966
Human papillomavirus-encoded circular RNA circE7 promotes immune evasion in head and neck squamous cell carcinoma., PMID:39366979
KLHDC8A Regulates M1/M2 Macrophage Polarization Through the PD-1/STAT3 Pathway to Promote Papillary Thyroid Cancer Development., PMID:39327249
For research use only. Not for human or drug use.
